New pill takes aim at Hard-to-Treat cancers

NCT ID NCT06209385

Completed Disease control Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the body and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YZJ-5053 (also called SHY-1901) tablets
What this could lead to: If safe and effective, this could lead to a new oral treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Shandong Cancer Hospital

Jinan, Shandong, 250000, China
Shanghai East Hospital

Shanghai, Shanghai Municipality, 200120, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330000, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.